Table 1.

Drugs targeting the IL-20 family of cytokines with relevance to immune mediated inflammatory arthritis.

Function	Name	Disease	Phase	Conclusion	Trial and reference
IL-20 inhibition	Fletikumab (NN8226, NNC0109-0012)	Healthy volunteers, psoriasis, and RA	1	Safe and well tolerated	NCT01038674 (70)
		Psoriasis	1	The expansion phase was terminated early due to apparent lack of efficacy (PASI improvement)	NCT01261767 (71)
		RA	2a	Effect in seropositive RA patients as early as week 1 with further improvements to week 12 (ACR responses)	NCT01282255 (72)
		RA	2b	Ended, no final data released	NCT01636817 and NCT01636843
IL-22 inhibition	Fezakinumab (ILV-094)	Healthy volunteers	1	Ended, no final data released	NCT00434746
		Psoriasis	1	Ended, no final data released	NCT00563524
		RA	2	Ended, no final data released	NCT00883896
		Atopic dermatitis	2	Skin improvement (CONRAD scores)	NCT01941537 (73)
IL-22RA1 inhibition	ARGX-112	Atopic dermatitis	Pre-clinical
IL-22R activation	Promenakin (F-652)	Colitis	Pre-clinical
		Acute alcoholic hepatitis	2	Ongoing	NCT02655510
		Graft versus host disease	2	Ongoing	NCT02406651
	RG7880 (UTTR1147A)	Healthy volunteers, ulcerative colitis and Crohn's disease	1	Safe and well tolerated	NCT02749630 (74)
		Diabetic foot ulcer	1	Ongoing	NCT02833389
		Ulcerative colitis	2	Ongoing	NCT03558152
JAK1 or TYK2 inhibition	E.g., tofacitinib and baricitinib	Immune mediated inflammatory diseases	Several	Efficacy in RA, SpA, and psoriatic arthritis	Several published and ongoing studies